The question of the use of Andexxa, a reversal agent for Factor Xa Inhibitors, has been batting around my brain for a few months now. We are in the unfortunate position of having a drug with very questionable evidentiary support but with an FDA labelled indication. I received an email from the lead author of paper just published in Neurocritical Care.

* Peled et al. Key Points to Consider When Evaluating Andexxa for Formulary Addition. Neurocrit Care 10.1007/s12028-019-00866-6

Dr. Harry Peled is the medical director of Cardiology and Critical Care at St Jude Medical Center in California. Relevantly, he is also chair of the Pharmacy an Therapeutics Committee.

I would love to hear your thoughts on this issue--place them in the comments below.

See Also

* I Have Issues with Andexanet by K. Kipp, PharmD

Update:

* In-Vivo Trial of 4-Factor PCC for Reversal of Xas

Now on to the Podcast...